Keytruda, Tecentriq Face Efficacy Questions In Urothelial Cancer

17:30 EDT 21 May 2018 | SCRIP

Monotherapy patients with tumors that have low PD-L1 expression experienced decrease survival in two confirmatory trials; however, the immune checkpoint...

Original Article: Keytruda, Tecentriq Face Efficacy Questions In Urothelial Cancer

More From BioPortfolio on "Keytruda, Tecentriq Face Efficacy Questions In Urothelial Cancer"